Expansion of the product portfolio through the transfer of 4 products from Nippon Pharmaceutical
First written in FY2022-Q2. 4 of 6 entries say "Restated". Latest entry: FY2023-Q3.
No other company in this theme has enough history to compare yet.
- FY2023-Q3RestatedAnnual report
「We are working to expand sales of the products transferred from 日本製薬株式会社, including Salprep Combination Oral Solution, as formulations expected to generate synergies with our future biosimilar business.」
The company continues to pursue sales expansion for the products transferred from 日本製薬, anticipating synergies with its future biosimilar business. - FY2023-Q2RestatedAnnual report
「We are working to expand sales of the products transferred from 日本製薬株式会社, including Salprep Combination Oral Solution, as formulations expected to generate synergies with our future biosimilar business.」
The company continues to pursue sales expansion for the products transferred from 日本製薬, anticipating synergies with its future biosimilar business. - FY2023-Q1RestatedAnnual report
「We are working to expand sales of the products transferred from 日本製薬株式会社, including Salprep Combination Oral Solution, as formulations expected to generate synergies with our future biosimilar business.」
The company continues to pursue sales expansion for the products transferred from 日本製薬, anticipating synergies with its future biosimilar business. - FY2022AdvancedAnnual report
「In December 2021, the company entered into an asset transfer agreement with 日本製薬株式会社 under which the manufacturing and marketing approvals for 4 products—Foliamin® (injection, tablets and 100 mg/g powder), Salprep® Combination Oral Solution, Minkuria® Oral Spray 0.8% and Osvan® Disinfectant Solution (0.025%, 0.05%, 0.1%, 10% and Osvan Rubbing®)—were transferred, and the transfer was completed.」
The company states that the transfer of the manufacturing and marketing approvals for 4 products from 日本製薬 was completed after the agreement was signed. - FY2022-Q3RestatedAnnual report
「In December 2021, the company entered into an asset transfer agreement with 日本製薬株式会社 to assume the marketing authorizations for 4 products: "Foliamin® (injection, tablets and powder 100mg/g)," "Salprep® combination oral solution," "Minclear® oral spray solution 0.8%," and "Osban® disinfectant solution (0.025%, 0.05%, 0.1%, 10% and Osban Rubbing®)." Many of these formulations are expected to generate synergies with the future biosimilars business, and the company is steadily laying the groundwork for future biosimilar sales.」
The company continues to disclose the asset transfer agreement under which the manufacturing and marketing approvals for 4 products were transferred from 日本製薬, and the positioning of the products in anticipation of future biosimilar sales. - FY2022-Q2First statedAnnual report
「In December 2021, the company entered into an asset transfer agreement with 日本製薬株式会社 to assume the marketing authorizations for 4 products: "Foliamin® (injection, tablets and powder 100mg/g)," "Salprep® combination oral solution," "Minclear® oral spray solution 0.8%," and "Osban® disinfectant solution (0.025%, 0.05%, 0.1%, 10% and Osban Rubbing®)." Many of these formulations are expected to generate synergies with the future biosimilars business, and the company is steadily laying the groundwork for future biosimilar sales.」
In December 2021, the company entered into an asset transfer agreement with 日本製薬 and acquired the manufacturing and marketing approvals for 4 products. The company positions these products as a foundation for future synergies with its biosimilar sales business.